Natural History of Untreated Nonsurgical Hepatocellular Carcinoma

OBJECTIVE:Hepatocellular carcinoma (HCC) is common in Asia, and the majority are not suitable for curative surgical treatment. We studied the natural history of untreated nonsurgical HCC to examine whether the prognosis has changed with improved supportive treatment and to identify factors affecting survival.METHODS:One hundred and six ethnic Chinese patients with HCC not amenable to curative treatment were managed symptomatically as control-arm patients in three randomized studies conducted between January 1996 and April 2001. Seventy-six (71.7%) patients were positive for hepatitis B surface antigen (HBsAg). Prognostic variables for survival were identified by univariate analysis and were subjected to a multivariate Cox analysis to identify the independent predictors of survival.RESULTS:All but four patients were followed until death. Common causes of death were tumor progression (63.2%) and liver failure (31.1%). The overall median survival was 3 months, and the 1-yr survival was 7.8% only. The median survival of patients of Okuda stages I, II, and III were 5.1 months, 2.7 months, and 1.0 month, respectively (p < 0.05 for comparison between any two stages). Multivariate analysis revealed four independent prognostic variables, namely, serum bilirubin, blood urea, serum alpha-fetoprotein, and Okuda stage.CONCLUSIONS:The prognosis of untreated HCC not suitable for curative treatment in Asia is grave despite improved supportive treatment. The four prognostic variables identified in this study are important in the decision for palliative treatment, and the Okuda staging remains an important prognostic guide.

[1]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[2]  C. Lai,et al.  Clinical features of hepatocellular carcinoma: Review of 211 patients in Hong Kong , 1981, Cancer.

[3]  N. Nagasue,et al.  The natural history of hepatocellular carcinoma. A study of 100 untreated cases , 1984, Cancer.

[4]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.

[5]  L. Papoz,et al.  Prognostic factors in patients with hepatocellular carcinoma attempts for the selection of patients with prolonged survival , 1987, Cancer.

[6]  C. Lui,et al.  Hepatocellular carcinoma in Hong Kong: clinical study on 340 cases. , 1990, Oncology.

[7]  L. Bolondi,et al.  Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival , 1992, Hepatology.

[8]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[9]  S. Hadziyannis,et al.  Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial , 1995, Hepatology.

[10]  S. Pignata,et al.  Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial , 1998, The Lancet.

[11]  V. Sriuranpong,et al.  Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. , 1998, American journal of clinical oncology.

[12]  J. Vauthey,et al.  Pathological aspects of hepatocellular carcinoma: a critical review of prognostic factors. , 1998, Hepato-gastroenterology.

[13]  E. Kouroumalis,et al.  Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study , 1998, Gut.

[14]  S. Fan,et al.  Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. , 1999, Annals of surgery.

[15]  J. Bruix,et al.  Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials , 1999, Hepatology.

[16]  A. Moles,et al.  Natural history of inoperable hepatocellular carcinoma: Estrogen receptors' status in the tumor is the strongest prognostic factor for survival , 2000, Hepatology.

[17]  J. Bruix,et al.  Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma , 2000, Hepatology.

[18]  Bernardino,et al.  Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma , 2000, Hepatology.

[19]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[20]  P. Tangkijvanich,et al.  Clinical Characteristics and Prognosis of Hepatocellular Carcinoma: Analysis Based on Serum Alpha-fetoprotein Levels , 2000, Journal of clinical gastroenterology.

[21]  Bellia Mario,et al.  Prospective validation of the CLIP score, a new prognostic system for cirrhotic patients with hepatocellular carcinoma (RE: Hepatology 2000, 32/3: 679-80) , 2000 .

[22]  S. Fan,et al.  Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study , 2000, American Journal of Gastroenterology.

[23]  K. Shirabe,et al.  [Prognostic factors in patients with hepatocellular carcinoma]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[24]  T M Therneau,et al.  A model to predict survival in patients with end‐stage liver disease , 2001, Hepatology.

[25]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[26]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[27]  H. El‐Serag Hepatocellular carcinoma: an epidemiologic view. , 2002, Journal of clinical gastroenterology.

[28]  S. Fan,et al.  A randomized placebo‐controlled study of long‐acting octreotide for the treatment of advanced hepatocellular carcinoma , 2002, Hepatology.

[29]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[30]  L. Castagnetta,et al.  Epidemiology, Risk Factors, and Natural History of Hepatocellular Carcinoma , 2002, Annals of the New York Academy of Sciences.

[31]  D. Machin,et al.  Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Kudo,et al.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score) , 2003, Journal of Gastroenterology.

[33]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[34]  F. Farinati,et al.  Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma , 1992, Digestive Diseases and Sciences.

[35]  E. Xiao,et al.  [Transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma]. , 2005, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[36]  D.,et al.  Regression Models and Life-Tables , 2022 .